bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.10.29.762608

Integrated transcriptomic and epigenomic profiling of human cartilage reveals coordinated changes in fibronectin expression, splicing, and receptor signaling during osteoarthritis progression

Abstract

Osteoarthritis (OA) is defined by progressive loss of articular cartilage, but how chondrocytes change as the disease advances is unclear because most studies have focused on end-stage tissue. We profiled human knee articular cartilage across the full range of macroscopic OA grade, from young healthy to aged severe OA donors, by bulk RNA sequencing of 92 knees, single-nucleus RNA sequencing of 108,600 chondrocyte nuclei from 30 donors and single-nucleus multiome sequencing of 24 of these donors, treating grade as a continuous variable. With increasing grade, cartilage increased extracellular matrix (ECM) synthesis and remodeling genes, lost glucocorticoid-responsive, lipid-metabolic and antioxidant programs, and changed the splicing of a small set of ECM transcripts, led by the extra domain B (EDB) exon of fibronectin (FN1). Nine chondrocyte clusters were present in every disease stage and formed a continuum ordered by cartilage zone and hypertrophic differentiation, with PRG4+ superficial and COL10A1+ hypertrophic chondrocytes as the only distinct cell types at its ends and a pre-hypertrophic state between them. With grade, all clusters shared a response in which ECM production rose and homeostatic programs fell, and they differed in which of its components was strongest: ECM production in the superficial cells, the secretory pathway in the hypertrophic and CYTL1+ cells, and inflammatory signaling in the ANXA1+ and CRISPLD2+ cells. Inferred communication between chondrocytes was remodeled with stage. FN1 was induced in every cluster in excess of its fibril-assembly machinery, together with the fibronectin-cleaving protease HTRA1, and FN1 signaling shifted in receptor use from integrin 5{beta}1 toward CD44 and, less robustly, v{beta}8, accompanied by a rise in TGF-{beta}/SMAD response genes. In four early-OA donors, tenascin-C was already largely induced and the FN1 receptor shift from 5{beta}1 toward CD44 was partly present, whereas the rise of FN1 outside superficial chondrocytes, of FGF1 and of developmental and ossification programs came with progression. Chromatin accessibility changed in the same direction across clusters, with regions linked to FN1 opening and regions linked to ITGA5 closing. OA progression in human cartilage therefore appears to be a change of chondrocyte state that differs in emphasis along a zonal and hypertrophic continuum and includes changes in fibronectin regulation, production, processing, and receptor engagement.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lotz, M., Swahn, H., Sakamoto, T., Kenvisay, C., Olmer, M., Uchida, Y., Asahara, H., Miller, R. E., Malfait, A.-M., Orange, D. E., Mehta, B., Otero, M., Bugbee, W. D.. 2026-11-03. Integrated transcriptomic and epigenomic profiling of human cartilage reveals coordinated changes in fibronectin expression, splicing, and receptor signaling during osteoarthritis progression. https://doi.org/10.64898/2026.10.29.762608

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Classifying tumors from broad category to hierarchical molecular subtype: an interpretable hierarchical framework for precision oncology

Precise tumor subtype classification is important for guiding personalized treatment, characterizing tumor heterogeneity, and investigating molecular mechanisms. However, most existing multi-label classification models use flat architectures and do not fully exploit the inherent hierarchical relationships and biological constraints among tumor types, which limits their performance and interpretability in complex, fine-grained pan-cancer classification. Here, we present the cancer Hallmark-based Hierarchical Recursive Model (HHRM) for pan-cancer hierarchical multi-label classification. HHRM integrates hierarchical label structures with recursive neural networks, enabling simultaneous modeling of multi-level dependencies from broad cancer categories to specific subtypes. We trained the model on a comprehensive pan-cancer cohort of 11,476 samples spanning 26 primary cancer types and 405 subtypes across up to eight hierarchical levels. HHRM achieved an accuracy of 0.7924 for predicting hierarchical tumor subtypes and was further evaluated on a validation dataset of 887 samples. Compared with other hierarchical modeling frameworks, HHRM achieved higher accuracy in all three output modes. Ablation experiments showed that replacing the hallmark-based graph convolutional network reduced model performance. On an independent dataset of 1,608 breast cancer samples, HHRM also achieved an accuracy greater than 0.86. Finally, we combined SHAP with a network-based method to rank and analyze predictive genes at different levels of the tumor hierarchy, which identified both known and potentially novel biomarkers for cancer diagnosis. In conclusion, to our knowledge, HHRM is the first hierarchical model for multi-level tumor subtype classification. Its competitive performance, combined with post hoc biological interpretation, suggests potential value for precision cancer diagnosis.

bioinformatics↗

A comparative transcriptomic framework across kidney organoid, assembloid, and transplantation models

Human kidney organoids recapitulate key aspects of renal development and have emerged as valuable platforms for disease modeling, nephrotoxicity screening, and therapeutic development. The field now includes a wide range of emerging protocols with distinct cellular compositions and maturation states, which complicates systematic comparison and model selection. Here, we integrated single-cell and single-nucleus transcriptomes from 11 studies spanning kidney organoid and assembloids, both in vitro and following transplantation, benchmarked against fetal and adult kidney references. Transcriptional maturation toward adult identity is compartment specific and does not correlate with protocol complexity. Assembloid protocols show the most adult-like podocyte and distal nephron signatures, transplantation is associated with enhanced tubular oxidative metabolic features, only protocols incorporating ureteric progenitors reliably generate collecting-duct lineages, and no protocol achieves mature adult proximal tubule identity. Annotating against either fetal or adult kidney reference alone leads to misassignment, because early fetal nephron epithelium transcriptionally resembles injury-dedifferentiated adult proximal tubule cells. Assembloid and transplantation models share elevated mechanosensing pathway expression independently of vascularization. Together, these findings provide a framework for kidney organoid model selection.

bioinformatics↗

OncoSpot enables benchmarking of cancer spatial transcriptomics methods across tumor evolutionary modes

Spatial transcriptomics (ST) is increasingly used to map clonal architecture within tumors, yet methods for analyzing cancer ST data are difficult to evaluate because real tumors lack ground truth for copy-number alterations (CNAs), subclonal identity, and malignant cell fraction. Existing ST simulators model normal tissue and do not represent tumor evolution, CNA-driven expression, or the spatial organization of malignant subclones. We present OncoSpot, a cancer-aware simulator of Visium-like spot-based ST data. OncoSpot combines a spatial evolutionary scaffold from DEMON, CNAs generated along the resulting clonal phylogeny with CNAsim, cancer-type-specific malignant transcriptional programs, and spatially clustered nonmalignant cell types, and aggregates cells into spots with known malignant fraction, subclone, and copy-number profiles. We demonstrate OncoSpot on high-grade serous ovarian carcinoma, colorectal cancer, and hepatocellular carcinoma, which represent three distinct modes of tumor evolution. Simulated subclones were spatially clustered and showed stronger phylogeny-space concordance than those generated by scCube under matched subclone populations. Benchmarking CopyKAT, CancerFinder, Clonalscope, and RCTD revealed cancer-dependent performance: Clonalscope recovered copy-number signals more accurately in ovarian and colorectal cancer, whereas CopyKAT performed better in hepatocellular carcinoma, reflecting both the assumptions of each method and the copy-number landscapes of the three cancers. OncoSpot's ground truth also exposed a failure mode in Clonalscope's malignant spot identification, in which tumor and normal labels were inverted, and allowed us to trace its cause. These method-dependent behaviors would be difficult to detect in real data. OncoSpot provides a framework for benchmarking CNA inference, subclone detection, malignant spot identification, and normal spot deconvolution, and its modular design and guidelines allow extension to additional cancer types. OncoSpot is freely available at https://github.com/compbio-mallory/OncoSpot.

bioinformatics↗